<DOC>
	<DOCNO>NCT01518387</DOCNO>
	<brief_summary>The purpose study assess effect reduction serum phosphate safety BAY77-1931 ( lanthanum carbonate ) patient hyperphosphatemia undergo continuous ambulatory peritoneal dialysis .</brief_summary>
	<brief_title>Open Study BAY77-1931 ( Lanthanum Carbonate ) Continuous Ambulatory Peritoneal Dialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>Serum phosphate level : &gt; 5.0 mg/dL &lt; 11.0 mg/dL 2 week initiation washout period Outpatient Undergoing CAPD least previous 3 consecutive month Who may enable continue CAPD Serum phosphate level &gt; =10.0 mg/dL start washout period &gt; =11.0 mg/dL 2 week Corrected serum calcium level &lt; 7.0 mg/dL start washout period &gt; =11.0 mg/dL 2 week Serum intact PTH ( Parathyroid ) &gt; =1000 pg/mL start washout period Pregnant woman , lactate mother Significant gastrointestinal disorder include know acute peptic ulcer Liver dysfunction History cardiovascular cerebrovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Hyperphosphatemia ESRD ( End Stage Renal Disease ) patient dialysis</keyword>
</DOC>